semaglutide 1.5 mg side effects Dosing Comparative safety and side effects

These effects, although generally transient, can limit treatment adherence, highlighting the need for appropriate monitoring and management during drug use (Sillassen et al, 2024)

Retatrutide: Not available

This randomized phase 2a #ClinicalTrial demonstrates that TPN171H, a potent and selective PDE5 inhibitor, significantly reduces pulmonary vascular resistance and improves acute hemodynamics in patients with #PulmonaryArterialHypertension (PAH), establishing it as a promising and well-tolerated oral therapeutic candidate for managing PAH

Remarkable Weight Loss Results With Retatrutide in Obesity Management Most participants who received retatrutide experienced substantial weight loss, although there was individual variability due to the heterogeneity of obesity

The cost savings are significant: compounded semaglutide at $149 to $397 per month versus $1,000+ for brand-name Wegovy

Further reading FcRn blockade in CIDP (ADHERE trial) The Lancet Neurology 2024 #PatientEducation #CIDP #Neuromuscular #EvidenceBasedMedicine Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial thelancet.com To view or add a comment, sign in Platelet Hyperreactivity: A Novel Peripheral Biomarker for Preclinical Alzheimers